Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer

Distinct lung microbiome patterns identified in Portuguese patients with lung cancer

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Cracking the code: Bispecific immunotherapy in small cell lung cancer

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC

Durvalumab after SBRT reduces tumour progression in early-stage NSCLC

Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer